Physician profile
Todd D Tillmanns
NPI 1720017577
$126,571.95
in general payments reported to CMS, 2019-2025
47 companies · $27K in 2025
The $27K reported for 2025 was more than what 95% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,824 · 2020: $5,263 · 2021: $19K · 2022: $10K · 2023: $30K · 2024: $25K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Consulting Fee: $4,419 · Food and Beverage: $4,299 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,871 · Education: $2,033 · Travel and Lodging: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,585.00 |
| Consulting Fee | $4,418.75 |
| Food and Beverage | $4,298.52 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,871.25 |
| Education | $2,032.83 |
| Travel and Lodging | $1,278.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $54,926.25 | 2020-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals Lp | $27,692.08 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Eisai INC. | $26,526.64 | 2021-2025 | |
| Intuitive Surgical, INC. | $9,166.42 | 2020-2025 | |
| Abbvie INC. | $2,537.10 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $1,628.25 | 2020-2022 | |
| Momentis Surgical INC. | $1,490.00 | 2022 | |
| Clovis Oncology, INC. | $458.15 | 2019-2021 | |
| Tesaro, INC. | $313.45 | 2019 | |
| Merck Sharp & Dohme LLC | $274.75 | 2019-2025 | Keytruda, Lynparza |
| Seagen INC. | $188.35 | 2022-2023 | Tivdak, Tukysa |
| Pfizer INC. | $175.26 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $155.82 | 2021-2023 | Epkinly, Imbruvica |
| Immunogen, INC. | $138.88 | 2023-2024 | Elahere, Elahere |
| Takeda Pharmaceuticals U.S.A., INC. | $80.57 | 2019-2023 | Ninlaro |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $70.17 | 2023-2025 | Imbruvica, Talvey, Rybrevant |
| Novartis Pharmaceuticals Corporation | $58.34 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $50.77 | 2022-2023 | Rezlidhia, Tavalisse |
| Stryker Corporation | $45.41 | 2022 | |
| Puma Biotechnology, INC. | $45.19 | 2021-2023 | Nerlynx |
| Jazz Pharmaceuticals INC. | $39.99 | 2022-2023 | Zepzelca |
| Daiichi Sankyo INC. | $37.18 | 2019-2021 | |
| Tersera Therapeutics LLC | $35.73 | 2023-2024 | Xermelo, Zoladex |
| Genzyme Corporation | $29.97 | 2021-2022 | |
| Gilead Sciences, INC. | $27.55 | 2025 | Trodelvy |
| Verastem, INC. | $26.78 | 2025 | Avmapki Fakzynja Co-Pack |
| Lilly USA, LLC | $23.43 | 2023 | Jaypirca |
| Regeneron Healthcare Solutions, INC. | $22.47 | 2025 | Libtayo |
| Dilon Technologies, INC. | $22.30 | 2025 | Hemoblast Bellows |
| Caris Mpi, INC. | $20.81 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $20.52 | 2024 | Phesgo, Hemlibra, Alecensa |
| Syndax Pharmaceuticals, INC. | $20.50 | 2025 | |
| Tempus Ai, INC | $20.12 | 2024 | |
| Ethicon US, LLC | $19.02 | 2025 | Enseal |
| Adc Therapeutics America, INC. | $18.22 | 2023 | |
| Kyowa Kirin, INC. | $17.65 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.36 | 2025 | Givlaari |
| Acrotech Biopharma INC. | $15.90 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $15.77 | 2022 | |
| Incyte Corporation | $15.76 | 2024 | Monjuvi |
| Taiho Oncology, INC. | $15.74 | 2024 | |
| G1 Therapeutics, INC. | $15.60 | 2023 | Cosela |
| Medtronic, INC. | $14.41 | 2023 | Truclear |
| Amgen INC. | $13.16 | 2021 | |
| Tactile Systems Technology INC | $12.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Tillmanns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.